Cost-effectiveness of nurse-led home monitoring of serum urate for gout patients starting with urate-lowering therapy in secondary care: a modeling study
Main finding · Incremental net monetary benefitResult — go to the resultMean iNMB 91.43 € CrI −56.49 to 274.09Authors' conclusion
This modeling study demonstrates that nurse-led home monitoring of serum urate levels in gout patients starting ULT is likely to be cost-effective compared to usual secondary gout care.
Study context
- Population
- Gout patients starting urate-lowering therapy (ULT) in a secondary care setting
- Comparison
- Nurse-led home monitoring of serum urate (SU) vs usual care
- Outcome
- Cost-effectiveness (iNMB; health outcomes in Quality-Adjusted Life Years (QALYs))
- Follow-up
- Two years
Methodological detailssocietal perspective, decision tree (6-month period) and Markov model (18 months), probabilistic sensitivity analyses, €20,000 per QALY willingness-to-pay threshold
- Societal perspective
- Decision tree (6-month period) and Markov model (18 months)
- Probabilistic sensitivity analyses
- €20,000 per QALY willingness-to-pay threshold
Main finding
Incremental net monetary benefit
Mean incremental net monetary benefit (iNMB)
91.43 €
CrI −56.49 to 274.09
As reported in the abstract
Further findings
QALYs over two years · QALYs changed marginally
Rheumatologist time · two years
- Rheumatologist time reduced
- 41 min (CrI −116 to 11)
Nurse time · two years
- Additional nurse time
- 52 min (CrI 4 to 143)
Original publication
Cost-effectiveness of nurse-led home monitoring of serum urate for gout patients starting with urate-lowering therapy in secondary care: a modeling study. Semin Arthritis Rheum. Published 16 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →